Tumor drug resistance remains a major challenge in the treatment of cancer. Here, we show that Prostatic secretory protein 94 (PSP94) levels are reduced in ovarian cancer patients with high levels of excision repair cross-complementing 1 (ERCC1), a marker for chemoresistance. We find that PSP94 is decreased in an ovarian cancer drug-resistant cell line, and plays an important role in the development of drug resistance in vitro. Our studies indicate that PSP94 can partially reverse drug resistance in mouse tumor models in vivo and that a PSP94 peptide derivative PCK3145 suppresses chemoresistant cancer cell and tumor growth in vitro and in vivo. Our investigation of the involved molecular mechanisms suggests that PSP94 may confer drug resistance by modulating the Lin28b/Let-7 signaling pathway. We introduce PSP94 and its peptide derivative PCK3145 as potential target to reverse chemoresistance in ovarian cancer and have begun to identify their relevant molecular targets in specific signaling pathways.
INTRODUCTION
Chemotherapy is a standard treatment for many human cancers. However, a critical cause of treatment failure is the development of drug resistance. Multiple mechanisms can lead to drug resistance, including drug efflux, modulation of drug metabolism, alteration of drug-induced damage, evasion of apoptosis 1,2 and dynamic chromatin modification. 3 Multi-drug resistance proteins, RPN2, b-catenin, PI3K and so on, have been reported as promising molecular targets for the reversal of drug resistance. [4] [5] [6] [7] However, no successful chemosensitizers or diagnostic assays for the prediction of an individual therapy response have been developed, yet. Tumor drug resistance involves a complex network of cellular pathways and molecular mechanisms 8 with numerous cross-interactions. A better understanding of these networks as they relate to drug-resistance development should lead to more effective strategies to overcome drug resistance or predict the individual therapy response.
Prostatic secretory protein 94 (PSP94), also known as b-microsemino-protein or MSMB, is found in a variety of human tissues and is the second most abundant protein in the semen of healthy men. [9] [10] [11] The level of PSP94 gradually decreases with the progression of prostate cancer and represents a promising mechanism for cancer treatment and a potential biomarker for early detection. 12 Notably, our preliminary observations show that PSP94 is misexpressed in ovarian cancer patients. 13 MicroRNAs (miRNAs) regulate gene expression at the posttranslational level. They participate in diverse biological functions such as cell proliferation, differentiation and apoptosis. 14, 15 The Let-7 family of miRNAs consists of more than ten sequenceconserved members with conserved functions across diverse species from worms to humans. 16 Deregulation of Let-7 has been linked to many types of cancer and other diseases. 16, 17 Lin28b, an RNA-binding protein was recently identified as a direct upstream target and inhibitor of the Let-7 family 18, 19 with important functions in embryonic stem cells and embryonal carcinoma cells. [20] [21] [22] [23] Signaling of Lin28b to Let-7 is crucial in development, and the deregulation of the balance between these two genes will result in various diseases. 24 This study was focused on PSP94, the long isoform of MSMB, and demonstrated decreased levels in ovarian cancer patients with high levels of excision repair cross-complementing 1 (ERCC1), a marker for chemoresistance. Our functional investigation showed a critical role of PSP94 in drug resistance, apparently by regulating downstream signaling of Lin28b/Let-7, and its peptide derivative PCK3145 selectively suppresses growth of resistant cancer cells in vitro and in vivo.
RESULTS

PSP94 expression is decreased in patients with high expression of ERCC1, a marker for chemoresistance in ovarian cancer
We have previously demonstrated in vitro and in human tissues that the essential nucleotide excision repair component, ERCC1 is associated with DNA repair and platinum resistance. 25, 26 Alternative studies suggested a role of ERCC1 as an overall prognostic biomarker for treatment and survival in testicular cancer and non-small cell lung cancer patients. 27 ,28 ERCC1 has thus been described as a potential biomarker for drug resistance. PSP94 levels were found altered in ovarian cancer patients and may play important roles in ovarian cancer treatment. 13 In the 1 current study we were interested in PSP94 expression in tumor samples with detectable ERCC1 representing the chemoresistant phenotype. 29 We examined the PSP94 mRNA level in 49 tumor samples from ovarian cancer patients by real-time quantitative PCR. PSP94 expression was found significantly reduced in tumor samples with high ERCC1 expression, suggestive of chemoresistance (average is 1.54, n ¼ 18), compared to patients with low expression of ERCC1, suggestive of chemosensitivity (average is 0.44, n ¼ 31), (Figure 1 , P ¼ 0.004). Our data are consistent with a decrease of PSP94 levels in patients with high levels of ERCC1, a marker for chemoresistance in ovarian cancer, suggesting a potential role of PSP94 in the development of chemoresistance. We also, albeit unsuccessfully, tried to demonstrate PSP94 protein in ovarian tumors by immunohistochemistry (data not shown), likely due to the low expression level of the gene in the ovary.
PSP94 plays important roles in acquired drug resistance To study the potential role of PSP94 in the development of chemoresistance, a drug-resistant cell line (O432-RP) was generated by paclitaxel treatment from the sensitive parental Ovca432 (O432) cell line. The IC 50 of paclitaxel action in O432-RP cells was found to be more than 100-fold higher than in the parental O432 cells (Supplementary Table 1 ). Western blot analysis comparing both cell lines showed PSP94 protein levels significantly reduced in O432-RP cells in contrast to the sensitive O432 cells (Figure 2a ). Subsequent studies focused on the potential roles of PSP94 in the development of drug resistance. (2) Knockdown of PSP94 expression by siRNA in drug-sensitive O432 cells. In contrast, siRNA knockdown of PSP94 led to a substantially reduced PSP94 protein level (Figure 2c-left-panel) . Proportionally to increasing doses of paclitaxel, survival of O432-psp-D cells was substantially elevated when compared to control O432 cells (Figure 2c graph) , suggesting that downregulation of PSP94 is sufficient to increase drug resistance.
We also overexpressed and knocked-down PSP94 in ovarian cancer cell line Caov-3, respectively, and assayed their impact on chemoresistant phenotypes. The similar phenomena were observed, for example, overexpression of PSP94 increases drug sensitivity (Supplementary Figure 1a) , and knockdown of PSP94 increases drug-resistant activity (Supplementary Figure 1b) . Our findings support an important role of PSP94 in the development of drug resistance in our experimental models.
In vivo. To evaluate whether PSP94 could be an effective therapeutic target to treat drug-resistant ovarian tumors, we 30,31 Thus, we evaluated PSP94 or PCK3145 whether this would also apply to drug-resistant cell growth in ovarian cancer. Upon treatment with PCK3145, we observed significantly reduced O432-RP, O432-RP-C and O432-PSP-D (O432 cells transfected with PSP94 siRNAs, which knockdown PSP94) cell survival when compared to vehicle PBS treatment, indicating that growth of resistant cells was significantly inhibited (Figure 3a , P ¼ 0.003, 0.004 and 0.026, respectively). In contrast, for treatment of O432, O432-Cs (O432 cells transfected with non-targeting siRNA) or O432-RP-psp-O cells, we did not observe a statistically significant difference between PCK3145 and PBS control treatments ( Figure 3a ). Our data show that PCK3145 represses the growth of drug-resistant cells with low PSP94 levels, but not of drug-sensitive cells, which express higher PSP94. We obtained similar results for cell treatment with recombinant protein PSP94 (data not shown). In addition, we treated O432-RP cells with PCK3145 alone and in combination with paclitaxel. The combination treatment was more effective than PCK3145 alone suggesting that PCK3145 re-sensitizes these cells and represses drug-resistant cancer ( Figure 3b , P ¼ 0.034, 0.015 and 0.001, respectively).
To test the potential of PCK3145 to treat drug-resistant tumors or as a chemosensitizer in vivo we extended our in vitro observations to a mouse tumor model. We treated O432-RP tumor-bearing animals with PCK3145 alone and in combination with paclitaxel. As shown in Figures 3c and d, drug-resistant tumor volume was significantly smaller at the end of treatment when compared to control PBS injection for both treatments (P ¼ 0.036 for PCK3145 alone; P ¼ 0.002 for PCK3145 plus paclitaxel).
We also examined the role of PCK3145 in the repression of chemoresistant cells in an alternative ovarian cancer chemoresistant cell line Uci101 (an experimental model that is resistant to several chemotherapeutic drugs 32 PSP94 mRNA levels were compared in tumors with high-ERCC1 levels (ERCC1 average 1.54, n ¼ 18) representing the chemoresistant phenotype, and in tumors with low-ERCC1 levels (ERCC1 average 0.44, n ¼ 31) representing the chemosensitive phenotype 25, 26 by real-time qPCR analysis. Relative levels of PSP94 in chemoresistant versus chemosensitive tumors are shown, respectively. **Po0.01. Mean±s.d. are given, and P-values (of duplicate samples) were calculated using the two-sided Student's t-test. data suggest that PCK3145 may be a potential target to reverse drug resistance in ovarian cancer. PSP94 may confer chemoresistance by modulating Lin28b and miRNAs of Let-7 pathway miRNAs play important roles in the development of drug resistance. 33, 34 To identify potential miRNAs involved in the PSP94-directed signaling network and to elucidate the molecular mechanisms of PSP94 in the development of drug resistance, we compared gene expression profiles between O432-RP-psp-O and O432-RP-C cells by PCR array analysis. Using human cancer miRNAqPCR array and miRNAqPCR (for other members of Let-7 family), we found that Let-7 (family) miRNA levels were significantly decreased in O432-RP-psp-O cells, when compared to control O432-RP-C cells (Figure 4a , Pso0.05). Based on this observation we also tested the expression of direct upstream signaling partners. Specifically, we evaluated protein expression levels of Lin28a and Lin28b, the RNA binding proteins and direct upstream regulators and inhibitors of the Let-7 family that negatively control Let-7 biosynthesis. 18, 19 We observed increased Lin28b protein levels in O432-RP-psp-O cells when compared to controls cells (Figure 4b ), but no difference was found for Lin28a expression (data not shown). In addition, we compared the expression levels of these genes between control and PSP94 knockdown O432-psp-D cells. As expected, Lin28b protein levels were decreased in O432-psp-D cells (Figure 4d ), whereas Let-7 miRNAs levels were increased in O432-psp-D cells when compared to control cells (Figure 4c , Pso0.05). When we compared protein levels of primary targets of Lin28b, c-myc and n-myc 35 and pluripotency genes Oct4 and Nanog, no significant changes were observed (data not shown). We also overexpressed Lin28b in drug-resistant O432-PR cells. As a result, these cells become less resistance when compared to the control (Supplementary Figure 3 , Pso0.05), supporting that Lin28b is involved in this chemoresistance network. Our findings suggest that in our experimental model PSP94 mediates chemoresistance partially by regulating Lin28b/Let-7 signaling pathway ( Figure 5 ).
DISCUSSION
Failure to respond to drug treatment or the development of drug resistance is a critical cause of treatment failure in chemotherapy, and many of the underlying molecular mechanism remain to be elucidated. In this study, we show that PSP94 expression is significantly decreased in tumor tissues of high ERCC1-expressing ovarian cancer patients. ERCC1 has been well described as a potential biomarker for drug resistance. [25] [26] [27] [28] Thus, PSP94 appears to play an important role in chemoresistance while the direct relationship between PSP94 expression and chemoresistance should be revealed when chemoresistance clinical data will become available in the future. We further demonstrate that Cell lines O432 (drug sensitive), O432-RP (drug resistant), O432-RP-psp-O (O432-RP cells transfected with PSP94 cDNA which overexpress PSP94 and display partially reversed drug resistance), O432-RP-C (O432-RP cells transfected with pCI-neo vector), O432-Cs (O432 cells transfected with non-targeting siRNA) and O432-psp-D (O432 cells transfected with PSP94 siRNA which increases drug resistance) were treated with PCK3145 (120 mg/ml) or control PBS, and assayed for cell survival 7-10 days later. Relative cell survival rates are shown. *Po0.05. Mean ± s.d. are given, and the P-values were calculated using the two-sided Student's t-test. (b) PCK3145 inhibits and re-sensitizes drugresistant cancer cells. O432-RP cells were treated with PCK3145 (120 mg/ml) and paclitaxel (30 ng/ml) alone or in combination and cell survival was assayed after 7-10 days. Relative cell survival rates are shown. *Po0.05; **Po0.01. Mean ± s.d. are given, and the P-values were calculated using the two-sided Student's t-test. (c) PCK3145 inhibits and re-sensitizes drug-resistant tumors. O432-RP cells were injected into either flank of mice. Mice (n ¼ 8 per group) were treated with PCK3145 (120 mg per kg per day) alone or in combination with paclitaxel (15 mgper kg per week) and control vehicle PBS for 2-3 weeks after tumors reached about 100 mm 3 . Tumors volumes before and after treatment are presented, respectively. *Po0.05, **Po0.01. Mean±s.d. are given, and P-values were calculated using the two-sided Student's t-test. PSP94 expression is decreased in an acquired chemoresistant ovarian cancer cell line. Our in vitro and in vivo data show a critical role of PSP94 in ovarian cancer chemoresistance, and restoration of PSP94 expression re-sensitizes resistant cells to drug treatment. Our findings demonstrate that recombinant PSP94 or its peptide derivative PCK3145 selectively repress growth of drug-resistant O432-RP cells, but had no significant effect on drug-sensitive O432 cells. In combination, our data suggest an important role of PSP94 in ovarian cancer chemoresistance and introduce PSP94 or PCK3145 as potential therapeutic agents.
PSP94 is a cysteine-rich, 94-amino acid secretory protein and represents one of the three predominant proteins secreted by a healthy human prostate gland. 36, 37 Note that its less common isoform PSP57 is composed of 57 amino acids. 38 PSP94 plays essential roles in prostate growth and development. Malfunction of this gene (such as by T to C substitution) has resulted in low PSP94 expression levels and susceptibility to develop prostate cancer. 12 Expression of PSP94 progressively decreases in prostate cancer, allowing its potential use as a prognostic biomarker. 12 In addition, both PSP94 and PCK3145 reduce prostate cancer growth in vivo consistent with their therapeutic potential for prostate cancer patients. 30, 31 While PSP94 has been well documented as a tumor suppressor and key player in prostate cancer, it has never been extended to other cancer types, although PSP94 is prominent in other organs, especially in female reproductive tissues such as the breast and ovaries. 11 In this study, we demonstrate such a role in chemoresistant ovarian cancer based on our in vitro, in vivo and clinical data. We reveal that PSP94 or PCK3145 may be a potential target for chemoresistance reversal in ovarian cancer. Based on our new findings and the reported potential in prostate cancer, PSP94 may have similar benefits in breast cancer/chemoresistance since PSP94 is expressed in human breasts. 30, 31 Peptide derivative PCK3145 represents PSP94 amino acids 31-45 and is believed to elicit the antitumor function of PSP94. When compared to the whole protein as a potential therapeutic agent, the small peptide derivative has particular advantages, including its higher tissue permeability, lower production cost, as well as its potential for conjugation to chemotherapeutic agents to facilitate a targeted delivery and avert cytotoxic side effects. 31 PCK3145 has already been shown to repress prostate tumor growth in experimental animals without significant side effects 30, 31 and it has been found safe and well-tolerated by prostate cancer patients in a clinical trial. 39 Based on our new findings and the existing data for prostate cancer we propose that PCK3145 may be equally valuable for ovarian cancer patients to treat chemoresistant tumors or to reverse chemoresistance.
Our findings also suggest a role of Lin28b/Let-7 signaling mechanisms downstream of PSP94 in drug resistance development. The Lin28/Let-7 pathway is believed to play a critical role in stem cell and cancer development. 14, 18, 19 Thus, our new findings point to a connection between drug resistance and stem cell development and oncogenesis. Lin28b or Lin28b/Let-7 signaling has been implicated in the development of resistance to radiation therapy for lung cancer 40 and of paclitaxel resistance in breast cancer. 41 Together with our new findings, a broader role of Lin28b/Let-7 signaling in chemo-and radio-resistance development to cancer treatment is gaining support by a number of studies. 40, 42 PSP94 may be involved in many of these processes, and alternative signaling pathways may play roles that remain to be investigated ( Figure 5 ). Our pathway analysis should have implications for a potential PSP94/PCK3145-based therapy since any gene in the implicated signaling network may affect the efficiency. For example, downregulation of Lin28 has been shown to suppress cancer cell growth. 21 We observed that siRNA knockdown Lin28b also inhibited the survival of ovarian cancer cells O432-RP-psp-O (Supplementary Figure 4 , P ¼ 0.003). Thus, a PSP94/PCK3145-based therapy in combination with Lin28b knockdown may enhance therapeutic efficacy.
In summary, our study shows that PSP94 may confer drug resistance in ovarian cancer. PSP94 or peptide derivative PCK3145 is introduced as a potential target for reversing chemoresistance, and a first set of the involved molecular targets and signaling mechanism has been identified.
MATERIALS AND METHODS
Human samples and ethics statement
Frozen GOG (Gynecologic Oncology Group) samples from patients with advanced ovarian cancer were obtained from the Cooperative Human Tissue Network (CHTN), Pediatric Division, Children's Hospital, Columbus, Ohio. Samples had been stripped off all patient identifiers before shipping to ensure that the presented molecular laboratory data cannot be linked with any patient. The tumor specimens were collected at primary surgery, freshly frozen in liquid nitrogen and stored at À 80 1C until RNA/DNA extraction. All samples were evaluated by pathologists.
Cell lines, cell culture and generation of drug-resistant sub-line All cell lines in this study were propagated as an adherent monolayer in MEM media (Invitrogen, Life Technologies, Carlsbad, CA, USA) except for Uci101, which was grow in RPIM 1640 (Invitrogen) at 37 1C in a humidified atmosphere of 5% CO 2 supplemented with 10% heat-inactivated FBS, 100 mg/ml penicillin and 100 mg/ml streptomycin. Human ovarian cancer parental cell lines O432 and Uci101 were provided by Dr Liu T of the Chinese Academy of Sciences. The O432-RP drug-resistant sub-cell line was generated from O432 cells by repeated paclitaxel (Sigma-Aldrich, Inc., St Louis, MO, USA) treatment at increasing concentrations for several cycles (each cycle including a 24 h exposure to the drug and subsequent recovery culture with normal medium for 10 days) until the cells were found resistant to drug treatment.
RNA extraction and cDNA synthesis
Total RNA from ovarian cancer tumors was partially purified by hot phenol/ chloroform extraction as previously reported. 43 cDNA was generated with oligo-dT primers from 5 mg of total RNA per sample (Life Technologies, Inc). Some total RNA was extracted using Trizol and cDNA was synthesized from 1 mg of total RNA by reverse-transcription using the Super Script Preamplification System (PE Applied Biosystems, Foster City, CA, USA). cDNAs were used for gene expression profiling. 
Immunoblotting
Cells were rinsed twice with PBS and total protein was solubilized in lysis buffer (150 mM sodium chloride; 50 mM Tris hydrochloride, pH7.5; 1% glycerol; 1% NP-40 substitute solution). Equal amounts of proteins were loaded and separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Proteins were transferred to a polyvinylidenedifluoride membrane, blocked in 5% skim milk, and probed with specific (primary) antibody, followed by treatment with secondary antibody conjugated to horseradish peroxidase (1:5000). Proteins were visualized by (enhanced) chemiluminescence detection (Pierce Biotechnology, Rockford, IL, USA) and exposed to X-ray film. Gapdh proteins were detected by normal chemiluminescence (Pierce Biotechnology) and exposed to less-sensitive X-ray film, resulting in a relatively weaker signal. Antibodies directed against PSP94, Lin28a/b, and myc were obtained from Abnova (Taipei, Taiwan); and antibodies for Gapdh, Oct4 and Nanog were obtained from Abcam (Cambridge, MA, USA).
siRNA and cDNA transfection Cells were transfected using Lipofectamine 2000 (Invitrogen) according the manufacturer's instructions with PSP94 or Lin28b siRNA duplexes (Ambion, Austin, TX, USA) or with PSP94 or Lin28b cDNA containing vectors (cDNAs had been amplified by Reverse-Transcription PCR and then cloned into a pCI-neo vector). For siRNA experiments, mock transfections and nontargeting siRNA were used as negative controls. All siRNAs experiments used two alternative siRNAs targeting the same gene to show knockdown and all experiments were repeated at least three times. Cells were treated for 72 h to allow for maximum knockdown, after which they were lysed for immunoblot analysis, RNA preparation or other assays. For cDNA transfection, a pCI-neo vector was used as a negative control. Geniticin was used to select stably expressing cells. siRNA oligos were purchased from Ambion.
Cell survival assay
Cells were counted and plated in culture dishes at 10-20% confluency on the day before treatment. Paclitaxel or control PBS was added for about 20 h and cells were cultured with normal medium for recovery and continuous propagation for about 10 days. To quantify final cell numbers, cells were stained with 0.25% crystal violet and 20% ethanol and then counted or the proliferation rate was measured by using a Cell Proliferation Assay kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. Briefly, MTS/PMS solution (at final concentrations of 333 mg/ml MTS and 25 mM PMS) was added to each well and cells were incubated for 2-3 h at 37 1C. The absorbance was determined at 490 nm using a 96-well plate ELISA reader. Culture medium was used as a background control. The experiments were repeated at least three times.
MiRNA isolation and profiling
Total cellular RNA was isolated using Trizol (Invitrogen). Two micrograms of total RNA were reverse-transcribed into cDNA using the QuantiMir RT Kit (System Biosciences), which converts all small RNAs simultaneously into detectable cDNAs for real-time PCR. MiRNA levels were quantified with an ABI PRISM 7900 instrument (PE Applied Biosystems). MiRNA expression was profiled using a cancer miRNA qPCR Array (System Biosciences, Mountain View, CA, USA) according to the manufacturer's instructions.
Tumor mouse model
Mouse experiments were carried out in compliance with the published guidelines of Laboratory Animal Care (NIH Publication No. 85-23, revised 1985; http://grants1.nih.gov/grants/olaw/references/phspol.htm) and the Care and Use of Laboratory Animals (National Research Council, 1996) . Four-to-six-week-old female BALB/cnu mice (Charles Rivers Laboratories and Laboratory Animal Research Center) were used to generate xenograft tumors. 1.0 Â 10 7 of experimental cells were suspended in 200 ml saline solution and injected into both flanks of mice. The mice were treated with paclitaxel (15 mg per kg per week), PCK3145 (120 mg per kg per day, Sanbo Inc., Beijing, China) or vehicle PBS by intratumoral injection for 2-3 weeks once tumors volumes reached about 100 mm 3 . Tumor volume and mouse weight were continuously monitored. The tumor volume was calculated using the formula ¼ a Â b2 Â 0.5236, where a is the longest diameter, b is the shortest diameter and 0.5236 is a constant to calculate the volume of an ellipsoid.
Statistical methods
The student's t-test was used to compare the differences between experimental groups. Statistical significance was defined as Po0.05. All statistical tests and corresponding P-values were two-sided.
